34 terminated. 34 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 34 | Terminated 34 |
| Phase 2 | 1 | Terminated 1 |
Follow Asthma: new trials by email Literature Review of Asthma trials Research Report on Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 654 | 2023-03-27 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 1061 | 2023-01-30 | 2025-12-15 |
| Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma Tezepelumab, Placebo - Asthma | Phase 3 | Terminated | AstraZeneca | 125 | 2022-08-09 | 2026-06-18 |
| AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department Azithromycin, Placebo - Asthma, Wheezing | Phase 3 | Terminated | University of Arizona | 840 | 2021-11-22 | 2026-06-23 |
| A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat REGN1908-1909, Matching Placebo - Allergic Rhinitis Due to Cat Allergy | Phase 3 | Terminated | Regeneron Pharmaceuticals | 446 | 2021-07-30 | 2024-06-11 |
| Protective Role of Inhaled Steroids for Covid-19 Infection 2: Usual practice + SYMBICORT RAPIHALER, 1: Usual practice - Covid-19 Infection, Hospitalization in Respiratory Disease Department | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 146 | 2020-04-13 | 2021-08-03 |
| Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy Brand Name: Flutiform K-haler - Asthma | Phase 3 | Terminated | Mundipharma Korea Ltd | 20 | 2019-11-26 | 2021-01-25 |
| Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) Benralizumab 30 mg, Matched placebo - Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis | Phase 3 | Terminated | AstraZeneca | 295 | 2019-11-25 | 2026-02-19 |
| Systemic Corticosteroids Avoidance Study in Severe Asthma Patients Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily - Asthma | Phase 3 | Terminated | Novartis Pharmaceuticals | 604 | 2018-12-13 | 2021-10-11 |
| A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol Test Product, Reference Product, Placebo - Asthma | Phase 3 | Terminated | Amneal Ireland Limited | 761 | 2018-12-06 | 2020-01-13 |
| Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study Dexamethasone, Prednisone - Asthma | Phase 3 | Terminated | Children's Hospital of Eastern Ontario | 20 | 2018-03-05 | 2020-09-07 |
| Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment QAW039 150 mg, QAW039 450 mg, Placebo - Asthma | Phase 3 | Terminated | Novartis Pharmaceuticals | 2538 | 2017-03-21 | 2020-10-12 |
| A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma reslizumab - Eosinophils, Asthma | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 391 | 2017-03-10 | 2022-12-14 |
| A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma Tralokinumab open-label - Inadequately Controlled Asthma | Phase 3 | Terminated | AstraZeneca | 28 | 2016-11-11 | 2019-09-06 |
| Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Mepolizumab, Placebo - Asthma | Phase 3 | Terminated | Johannes Gutenberg University Mainz | 29 | 2015-11-17 | 2017-07-13 |
| A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects levalbuterol tartrate HFA inhalation aerosol, placebo - Asthma | Phase 3 | Terminated | Sumitomo Pharma America, Inc. | 18 | 2014-07-01 | 2016-04-08 |
| Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma Benralizumab, Placebo - Asthma | Phase 3 | Terminated | AstraZeneca | 13 | 2013-11-01 | 2015-11-24 |
| A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication Lebrikizumab, Placebo, Standard of Care - Asthma | Phase 3 | Terminated | Hoffmann-La Roche | 346 | 2013-08-13 | 2026-06-30 |
| Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients SOTB07 200mg, SOTB07 400mg, SOTB 200mg placebo - Asthma | Phase 3 | Terminated | SK Chemicals Co., Ltd. | 194 | 2013-01-01 | 2016-01-28 |
Showing 20 of 34. Sign in to see all of them.
Pulmonary Eosinophilia (4) · Diabetes Mellitus, Type 1 (3) · Diabetes Mellitus, Type 2 (3) · Bronchial Diseases (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Respiratory Tract Diseases (2) · Bronchial Spasm (1) · COVID-19 (1) · Conjunctivitis, Allergic (1) · Diabetes Mellitus (1) · Dyspnea (1) · Gastroesophageal Reflux (1) · Hypersensitivity (1)
Hypersensitivity, Immediate (34) · Hypersensitivity (33) · Immune System Diseases (33) · Respiratory Hypersensitivity (33) · Bronchial Diseases (32) · Lung Diseases (32) · Lung Diseases, Obstructive (32) · Respiratory Tract Diseases (32) · Eosinophilia (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Hypereosinophilic Syndrome (4) · Leukocyte Disorders (4) · Autoimmune Diseases (3) · Endocrine System Diseases (3)
Albuterol (5) · benralizumab (2) · fevipiprant (2) · Azithromycin (1) · Beclomethasone (1) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Dexamethasone (1) · Formoterol Fumarate (1) · Insulin (1) · Insulin Aspart (1) · Ipratropium (1) · Lansoprazole (1) · Prednisone (1) · RNA aptamer SUP-A-004 (1)
AstraZeneca (5) · Amphastar Pharmaceuticals, Inc. (3) · Areteia Therapeutics (3) · Boehringer Ingelheim (2) · Mannkind Corporation (2) · Novartis Pharmaceuticals (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Allergan (1) · Amneal Ireland Limited (1) · Assistance Publique - Hôpitaux de Paris (1) · Children's Hospital of Eastern Ontario (1) · Hoffmann-La Roche (1) · Johannes Gutenberg University Mainz (1) · Mundipharma Korea Ltd (1) · Northwestern University (1)
United States (23) · Poland (11) · Argentina (9) · France (9) · Germany (9) · Brazil (8) · Canada (8) · Czechia (8) · Spain (8) · United Kingdom (8) · Mexico (7) · Russia (7) · Ukraine (7) · Belgium (6) · Bulgaria (6)
Brandon S Lu, MD, MS (1) · Carlos Barcina, MD (1) · Charlie Casper, PhD (1) · Fernando D Martinez, MD (1) · Irshad Haque (1) · Isabelle Campine, MD (1) · Kathryn Peterson, MD (1) · Kurt Denninghoff, MD (1) · Kwang Ha Yoo (1)
PMID 39393433, PMID 29536781, PMID 30552284, PMID 33710614, PMID 34895218, PMID 35846226, PMID 42149992, PMID 42150582
2023 (3), 2016 (2), 2005 (1), 2015 (1), 2018 (1)